Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

~16 mi. (Solna, Sweden, +176 more cities)

Karolinska Universitetssjukhuset Solna ( Site 2220)

Endometrial Carcinoma, +1 more condition

chemotherapy, +2 more drugs

chemotherapy, +2 more types

Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)

~16 mi. (Solna, Sweden, +115 more cities)

Karolinska Universitetssjukhuset Solna ( Site 2000)

ATM Loss, +27 more biomarkers

Breast Carcinoma, +2 more conditions

olaparib, +1 more drug

immunotherapy, +1 more type

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

~16 mi. (Solna, Sweden, +52 more cities)

Karolinska Institutet

MS4A1 Expression, +1 more biomarker

Blastoid Variant Mantle Cell Lymphoma, +12 more conditions

pirtobrutinib, +3 more drugs

chemotherapy, +2 more types

A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer

~16 mi. (Solna, Sweden, +87 more cities)

Karolinska Universitetssjukhuset - Solna

ALK Fusion

Non-Small Cell Lung Carcinoma

brigatinib

targeted therapy

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

~21 mi. (Stockholm, Sweden, +144 more cities)

Karolinska Universitetssjukhuset Solna ( Site 2100)

Clear Cell Renal Cell Carcinoma

belzutifan, +3 more drugs

immunotherapy, +1 more type

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

~21 mi. (Stockholm, Sweden, +89 more cities)

Karolinska Universitetssjukhuset Solna-Tema Cancer - ME Bröst- endokrina tumörer och sarkom ( Site 1

ER Positive, +2 more biomarkers

Breast Carcinoma

capecitabine, +4 more drugs

chemotherapy, +1 more type

Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)

~21 mi. (Stockholm, Sweden, +147 more cities)

Karolinska Universitetssjukhuset ( Site 0784)

Cervical Adenocarcinoma, +2 more conditions

brachytherapy, +3 more drugs

chemotherapy, +2 more types

Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

~21 mi. (Stockholm, Sweden, +199 more cities)

Karolinska Universitetssjukhuset, Huddinge ( Site 0689)

Hepatocellular Carcinoma

pembrolizumab

immunotherapy

Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

~21 mi. (Stockholm, Sweden, +163 more cities)

Karolinska Universitetssjukhuset Solna ( Site 1212)

Bladder Urothelial Carcinoma

cystectomy, +2 more drugs

chemotherapy, +3 more types

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

~21 mi. (Stockholm, Sweden, +209 more cities)

Onkologklinike Sodersjukhuset

ERBB2 Amplification, +1 more biomarker

Breast Carcinoma

ado-trastuzumab emtansine, +1 more drug

targeted therapy

TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

~21 mi. (Stockholm, Sweden, +144 more cities)

Karolinska Universitetssjukhuset Solna

EGFR Exon 20 Insertion

Non-Squamous Non-Small Cell Lung Carcinoma

mobocertinib

targeted therapy

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET) (MK-6482-015)

~21 mi. (Stockholm, Sweden, +29 more cities)

Karolinska Universitetssjukhuset Solna ( Site 1202)

Pancreatic Neuroendocrine Tumor, +1 more condition

belzutifan

targeted therapy